Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption

Bone

Volumn 34, Issue 1, 2004, Pages 187-194

  Hannon, Rosemary A ^a   Clowes, Jackie A ^a   Eagleton, Alison C ^a   Al Hadari, Amna ^a   Eastell, Richard ^a   Blumsohn, Aubrey ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alendronate; C terminal telopeptide of type I collagen; Diurnal rhythm; Haemodialysis; Tartrate resistant acid phosphatase; Variability

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ISOPROTEIN;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; EVALUATION; FEEDING; FEMALE; HEALTH STATUS; HEMODIALYSIS; HUMAN; IMMUNOREACTIVITY; KIDNEY CLEARANCE; KIDNEY FAILURE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; SERUM; URINALYSIS;

EID: 0942300651     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.04.002     Document Type: Article

References (41)

1. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., Christiansen C. Mechanism of circadian variation in bone resorption. Bone. 30:2002;307-313.
2. Blumsohn A., Herrington K., Hannon R.A., Shao P., Eyre D.R., Eastell R. The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endocrinol. Metab. 79:1994;730-735.
3. Blumsohn A., Naylor K.E., Assiri A.M., Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin. Chem. 41:1995;1592-1598.
4. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin. Chem. 40:1994;2022-2025.
5. Braga de Castro Machado A., Hannon R., Eastell R. Monitoring alendronate therapy for osteoporosis. J. Bone Miner. Res. 14:1999;602-608.
6. Cheung C.K., Panesar N.S., Haines C., Masarei J., Swaminathan R. Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin. Chem. 41:1995;679-686.
7. Clowes J.A., Hannon R.A., Yap T.S., Hoyle N.R., Blumsohn A., Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 30:2002;886-890.
8. Costa L., Demers L.M., Gouveia-Oliveira A., Schaller J., Costa E.B., de Moura M.C.et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. 20:2002;850-856.
9. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1994;1693-1700.
10. Gertz B.J., Clemens J.D., Holland S.D., Yuan W., Greenspan S. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 63:1998;102-106.
11. Glorieux F.H., Travers R., Lanoue G., Gineyts E., Delmas P.D. Tartrate-resistant acid phosphatase levels are an index of the number but not the activity of osteoclasts. Bone. 16:1995;101S.
12. Greenspan S.L., Rosen H.N., Parker R.A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J. Clin. Endocrinol. Metab. 85:2000;3537-3540.
13. Halleen J., Hentunen T.A., Hellman J., Väänänen H.K. Tartrate-resistant acid phosphatase from human bone: purification and development of an immunoassay. J. Bone Miner. Res. 11:1996;1444-1452.
14. Halleen J.M., Alatalo S.L., Ivanska K.K., Cheng S., Uusi-Rasi K., Nenonen A.et al. Serum tartrate-resistant acid phosphatase 5b is a useful marker for monitoring alendronate therapy. J. Bone Miner. Res. 16:2001;S534.
15. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Väänänen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 47:2001;597-600.
16. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Väänänen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 15:2000;1337-1345.
17. Halleen J.M., Hentunen T.A., Karp M., Kakonen S.M., Pettersson K., Väänänen H.K. Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J. Bone Miner. Res. 13:1998;683-687.
18. Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J. Bone Miner. Res. 13:1998;1124-1133.
19. Hannon R., Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 11(Suppl. 6):2000;S30-S44.
20. Hanson D.A., Weis M.A.E., Bollen A.-M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type 1 collagen cross-linked n-telopeptides in urine. J. Bone Miner. Res. 7:1992;1251-1258.
21. Janckila A.J., Takahashi K., Sun S.Z., Yam L.T. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin. Chem. 47:2001;74-80.
22. Ju H.S., Leung S., Brown B., Stringer M.A., Leigh S., Scherrer C.et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin. Chem. 43:1997;1570-1576.
23. Kraenzlin M.E., Lau K.H., Liang L., Freeman T.K., Singer F.R., Stepan J.et al. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J. Clin. Endocrinol. Metab. 71:1990;442-451.
24. Lam K.W., Li C.Y., Yam L.T., Desnick R.J. Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendotheliosis. Clin. Biochem. 14:1981;177-181.
25. Lau K.H., Onishi T., Wergedal J.E., Singer F.R., Baylink D.J. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin. Chem. 33:1987;458-462.
26. Looker A.C., Bauer D.C., Chesnut C.H. III, Gundberg C.M., Hochberg M.C., Klee G.et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos. Int. 11:2000;467-480.
27. Modderman W.E., Tuinenburg-Bol Raap A.C., Nijweide P.J. Tartrate-resistant acid phosphatase is not an exclusive marker for mouse osteoclasts in cell culture. Bone. 12:1991;81-87.
28. Oddie G.W., Schenk G., Angel N.Z., Walsh N., Guddat L.W., de Jersey J.et al. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone. 27:2000;575-584.
29. Panteghini M., Pagani F. Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen. Ann. Clin. Biochem. 33:1996;36-42.
30. Pedrazzoni M., Alfano F.S., Gatti C., Fantuzzi M., Girasole G., Campanini C.et al. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif. Tissue Int. 57:1995;25-29.
31. Popp-Snijders C., Lips P., Netelenbos J.C. Intra-individual variation in bone resorption markers in urine. Ann. Clin. Biochem. 33:1996;347-348.
32. Raggatt P.R. Duplicates or singletons? An analysis of the need for replication in immunoassay and a computer program to calculate the distribution of outliers, error rate and the precision profile from assay duplicates. Ann. Clin. Biochem. 26:1989;26-37.
33. Robins S.P., Woitge H., Hesley R., Ju J., Seyedin S., Seibel M.J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 9:1994;1643-1649.
34. Schiele F., Artur Y., Floc'h A.Y., Siest G. Total, tartrate-resistant, and tartrate-inhibited acid phosphatases in serum: biological variations and reference limits. Clin. Chem. 34:1988;685-690.
35. Stepan J.J., Lachmanova J., Strakova M., Pacovsky V. Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. Bone Miner. 3:1987;177-183.
36. Stepan J.J., Silinkova-Malkova E., Havranek T., Formankova J., Zichova M., Lachmanova J.et al. Relationship of plasma tartrate-resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin. Chim. Acta. 133:1983;189-200.
37. Stepan J.J., Silinkova-Malkova E., Havranek T., Formankova J., Zichova M., Lachmanova J.et al. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin. Chim. Acta. 133:1983;189-200.
38. Stepan J.J., Tesarova A., Havranek T., Jodl J., Formankova J., Pacovsky V. Age and sex dependency of the biochemical indices of bone remodelling. Clin. Chim. Acta. 151:1985;273-283.
39. Stevenson H.P., Leslie H., Sheridan B. Intra-individual variation in serum type I procollagen carboxy-terminal propeptide and type I collagen carboxy-terminal cross-linked telopeptide concentrations. Ann. Clin. Biochem. 34:1997;317-318.
40. Wichers M., Schmidt E., Bidlingmaier F., Klingmuller D. Diurnal rhythm of CrossLaps in human serum. Clin. Chem. 45:1999;1858-1860.
41. Yam L.T. Clinical significance of the human acid phosphatases: a review. Am. J. Med. 56:1974;604-616.